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ABSTRACT  
Objective: The goal of the present study was to develop niosomal gel as a nanocarrier for improved depigmentation effect of hydroquinone (HQ). As 
well as to evaluate the prepared niosomes for entrapment efficiency, transmission electron microscopy (TEM), zeta potential, and in vitro release 
study. As an ultimate point of the objectives was to evaluate the best-prepared niosomal gel formula clinically in well-diagnosed patients of 
melasma and the results were compared with a commercial product. 
Methods: The effect of incorporation of co-surfactant such as Tween 20, Tween 40, and Tween 60 with Span 80, was studied to determine the 
highest entrapment efficiency and the desired release rate. Niosomes showed the highest entrapment efficiency was incorporated in different 
gelling agents like Carbopol 934 and Carboxymethylcellulose sodium (CMC Na) with different concentrations. Accelerated stability testing of HQ 
from niosomal gel formulations; the expiry date t90 was estimated. The best-prepared niosomal gel formula was studied clinically in patients of 
melasma and the results were compared with the commercial product (Clearique 2%)®
Results: There was a significant increase in the clinical efficacy of the niosomal therapy and a highly significant decrease regarding to modified 
melasma area and severity index (MASI), duration to achieve improvement, side effects, and the recurrence of melasma in patients treated with 
niosomal gel compared to the commercial product. 
Delta Pharma Company.  
Conclusion: The incorporation of hydroquinone in niosomal gel improves its therapeutic effect regarding clinical effect, duration of treatment, side 
effects, recurrence and patient compliance. 
Keywords: Hydroquinone, Niosomes, Niosomal gel, Surfactants, Co-surfactants, In vitro drug release study, Depigmentation effect 
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INTRODUCTION 
Melasma is an acquired hyperpigmentary disorder on sunlight exposed 
skin of the face and neck, reported mainly among females with IV or V 
skin types. The etiology is unknown, but the most significant inclining 
factor is sun exposure. Other factors include pregnancy, contraceptives, 
race, hereditary factors and exogenous hormones [1, 2]. Melasma 
presents as dark macules distributed bilaterally symmetrical, with 
serrated and irregular margins. The three major patterns of distribution 
are: Centro facial (cheeks, forehead, upper lip, nose and chin) in 65% of 
cases, malar (cheeks and nose) in 20% of cases and mandibular (rami of 
the mandible) in 15% of cases [3, 4]. Niosomes are non-ionic surfactant 
vesicles (NISVs) that have the ability to encapsulate hydrophilic drugs or 
partitioning lipophilic drugs into vesicular bilayer membranes [5]. 
Niosomes are microscopic unilamellar or multilamellar spheroid 
structures formed upon combining non-ionic surfactants with 
hydrated mixtures of cholesterol (Chol). The niosomes bilayer 
membrane has high compatibility with biological membranes giving 
them augmented stability and duration in circulation [6]. Niosomes have 
pulled in a lot of consideration in the delivery of dermal medications 
because of the numerous favorable circumstances like they are 
biodegradable, biocompatible, non-toxic, non-immunogenic in nature 
and effective in the variation of drug release properties [7, 8]. According 
to their size and structure, these vesicles can be administered by routes 
like intramuscular, intravenous, ocular, subcutaneous, oral, pulmonary, 
intraperitoneal, and transdermal [9, 10]. 
Hydroquinone (HQ), 1, 4-benzenediol, is a depigmenting agent. It is 
the frequently utilized compound in skin-toning preparations, which 
was reported to be effective at 1.5–2.0%. Concentrations higher than 
5.0% were liable to cause redness and burning. The depigmenting 
activity of HQ may partially be associated with the capability of the 
compound to act as an alternate substrate of tyrosinase; competing 
for tyrosine oxidation inactive melanocytes [11-13].  
MATERIALS AND METHODS 
Materials 
HQ was a gift sample kindly supplied by Chemical Industrial 
Development Co., (CID) Giza, Egypt. Sorbitan mono-oleate (Span 80), 
Polyoxyethylene Sorbitan monolaurate (Tween 20), 
Polyoxyethylene Sorbitan monopalmitate (Tween 40), 
Polyoxyethylene Sorbitan monostearate (Tween 60), sodium sulfite, 
Carbopol 934, CMC Na, cholesterol, and cellulose membrane of the 
molecular weight cut off 10,000 were purchased from Sigma 
Chemical Co., Cairo, Egypt. Triethanolamine was purchased from 
Memphis Pharmaceutical Chemical Co. Egypt, CMC powder was 
purchased from El-Nasr Pharmaceutical Chemical Co. Egypt. 
Methods 
Preparation of drug-loaded niosomes 
All HQ-entrapped niosomes were prepared from a mixture of 
nonionic surfactant, Chol and co-surfactant (table 1). The total 
lipid concentration was 300 µmole. Mixtures of Chol, with a non-
ionic surfactant (span80) and co-surfactant (Tween 20, Tween 40, 
and Tween 60) in 1:0.5:0.5 molar ratio were dissolved in 15 ml 
chloroform in a 100 ml rounded-bottom [14]. The organic solvent 
was removed at a temperature of 60 °C under reduced pressure on 
a rotary evaporator to form a thin film on the flask wall. The 
excess organic solvent was then removed by leaving the flask in a 
desiccator under vacuum overnight. The obtained dried lipid film 
was hydrated with 5 ml of phosphate buffer solution (PBS) 
(pH7.4) containing HQ (2 mg/ml) and 0.05% sodium sulfite as an 
antioxidant [15] by shaking with a mechanical shaker in a water 
bath at 60 °C for about 1 h. The resulting multilamellar non-ionic 
surfactant vesicle dispersion was then stored at less than 4 °C for 
congealing [16]. 
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Table 1: Compositions of the prepared niosomal formulations 
Codes Chol (mg) Span 80 (mg) Tween 20 (mg)  Tween 40 (mg)  Tween 60 (mg)  
F1 58.005 32.1 92 - - 
F2 58.005 32.1 - 96.2  
F3 58.005 32.1  - 84.8 
Chol: cholesterol, all formulations contain HQ: 10 mg, Na2So3
 
: 0.05% 
Characterization of the prepared noisome formulations 
Morphology of formulated niosomal vesicles  
A drop of the dispersion was viewed under an optical microscope to 
observe the shape and lamellar nature of the vesicle. 
Photomicrographs were detected with a light microscope [17].  
Entrapment efficiency of drug-loaded niosomes 
The HQ-entrapped niosomes were separated from the 
unentrapped free drug by freeze-thawing/centrifugation method 
[18]. One ml samples of the prepared niosomal dispersions were 
frozen for 24 h at-20 °C in ependorf tubes. The frozen samples 
were removed from the freezer and centrifuged at 15,000 rpm for 
10 min. Niosomal pellets were suspended in PBS (pH 7.4) and then 
centrifuged again. This washing step was repeated two times to 
ensure that an un-entrapped drug was no longer present in the 
void volume between the niosomes [18]. Supernatant was 
separated as it contains an unentrapped drug, which is highly 
soluble in PBS 7.4, using a micro-pipette. To the remaining pellet 
in the centrifuge tube, 500 µl of 0.1 N NaOH (as the drug is highly 
soluble in 0.1N NaOH) was added and vortexed thoroughly for 3 
min. After vortexing, a white suspension was obtained and 1 ml of 
this suspension was taken with a micro-pipette and transferred to 
a test tube. To this 5 ml methanol was added, which resulted in a 
clear solution; this was further vortexed in a vortex mixer for 2 
min, such that to ensure that the niosomes are lysed completely to 
release the drug. This solution (1 ml) was further diluted with 
methanol and filtered using membrane filter and the absorbance 
was determined using a UV spectrophotometer at 295 nm [19]. 
The entrapment efficiency (EE) is expressed as  
 
Sa= Total amount of drug in the system, Sb= Amount of drug in the 
supernatant after centrifugation [18]. 
Transmission electron microscopy 
The prepared niosomal formulations with the highest entrapment 
efficiency were characterized for their morphology using TEM. To an 
aliquot of a suspension of prepared niosomal formulation, a 
sufficient quantity of 1% phosphor tungstic acid was added and 
mixed gently. A drop of the mixture was placed onto the carbon-
coated grid and drained off the excess. The grid was allowed to dry, 
and it was observed under TEM. Electron micrographs were taken at 
suitable magnification [17]. 
Sizing of the vesicles 
NISVs were mounted on a glass slide and examined under a phase-
contrast microscope with a magnification of 400x using a stage 
nanometer to determine the size of the vesicles. 
Zeta potential measurement 
Zeta potential of suitably diluted niosomal dispersion was 
determined using Zetasizer Nano ZS-90 at 25 °C. The working 
principle of the instrument is electrophoretic light scattering (ELS), 
which determines the electrophoretic movement of charged 
particles under an applied electric field from the doppler shift of 
scattered light for zeta potential determination [20].  
In vitro release of HQ from niosomes 
The in vitro release of HQ from different niosomal formulations was 
carried out using a dissolution-dialysis apparatus, the cell of which 
was developed in our laboratory. The diffusion cell consists of a 
hollow plastic cylinder (length 20 cm and an internal diameter 3 
cm). After separation of the free drug, an accurately measured 
amount of HQ niosomal formulations, equivalent to 2 mg of HQ was 
resuspended in 1 ml PBS (pH 7.4) and transferred to the diffusion 
cell to which a cellulose membrane of the molecular weight cut off 
10,000 was attached to one side, and immersed in a receptor 
compartment containing 100 ml PBS (pH 7.4). The temperature of 
the receptor compartment was maintained at 37 °C±0.5 °C. At the 
specified time interval for 24 h, 5 ml samples were withdrawn from 
the receptor compartment, and the drug was determined 
spectrophotometrically at λmax
The obtained results were compared with the In vitro release of 
plain drug using 2 mg of HQ dissolved in 1 ml PBS (pH 7.4) 
 295 nm. Each sample withdrawn was 
replaced by an equal volume of PBS pH 7.4 [21].  
Release kinetic evaluation 
Specific computer program was used to determine the kinetic 
parameters of the in vitro release of HQ from different niosomal 
formulations. Zero, and first-order kinetics as well as, Higuchi 
diffusion model, were tried 
Preparation of HQ niosomal gels 
to choose the most suitable kinetic order 
or model for hydroquinone release. 
An equivalent amount of HQ niosomal formulations to get 2% w/w 
(drug/gel) separated from the un-entrapped drug was incorporated 
into the structured gels [22]. 
Carbopol 934 and CMC Na were used as gelling bases 
Preparation of carbopol 934 gel 
A Weighted amount of Carbopol 934 (1%, 2%, 3% w/w) was 
dispersed in 100 ml distilled water and stirred magnetically at a high 
speed. Stirring was continued until a thin dispersion, without lumps, 
was obtained, then the stirring speed was reduced to allow foam to 
break and to maintain a good liquid turnover while adding the 
0.01% w/w of Triethanolamine required forming the gel [23]. 
Preparation of CMC Na gel 
Weighed amount of CMC Na (2%, 3% and 4% w/w) powder was 
sprinkled, gently, on 100 ml boiling distilled water and stirred 
magnetically at high speed. Stirring was continued until a thin hazy 
dispersion, without lumps, was formed. Leaving overnight in the 
refrigerator may be necessary for complete gel dispersion [24].  
The plain drug gel was prepared in the same method, but instead of 
incorporation of niosome, the plain drug would be incorporated to the 
best gel base concentration regarding physical properties, in vitro drug 
release and patient compliance for comparison with niosomal gel. 
Evaluation of HQ niosomal gels 
Colour, homogeneity and texture 
Colour, homogeneity and texture of the prepared niosomal gels were 
tested by visual examination.  
Determination of pH 
pH of the prepared niosomal gel formulations was determined by 
digital a pH meter using the following method: one g of the gel was 
diluted with 9 g of distilled water and shaken well. The pH 
measurements were repeated three times for each formula and the 
reading was the average [25]. 
Salem et al. 
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Table 2: Composition of different niosomal gel formulations 
Codes Niosomal composition Gel bases % w/w 
HQ Na2SO Chol 3 Span 80 Tween 40 Tween 60 Carbopol 934 CMC Na 
(mg) (mg) (mg) (mg) % % 
F2a1 2% 0.05% 58.005 32.1 96.2 - 1% - 
F2a2 2% 0.05% 58.005 32.1 96.2 - 2% - 
F2a3 2% 0.05% 58.005 32.1 96.2 - 3% - 
F2b2 2% 0.05% 58.005 32.1 96.2 - - 2% 
F2b3 2% 0.05% 58.005 32.1 96.2 - - 3% 
F2b4 2% 0.05% 58.005 32.1 96.2   - 4% 
F3a1 2% 0.05% 58.005 32.1 - 84.8 1% - 
F3a2 2% 0.05% 58.005 32.1 - 84.8 2% - 
F3a3 2% 0.05% 58.005 32.1 - 84.8 3% - 
F3b2 2% 0.05% 58.005 32.1 - 84.8 - 2% 
F3b3 2% 0.05% 58.005 32.1 - 84.8 - 3% 
F3b4 2% 0.05% 58.005 32.1 - 84.8 - 4% 
  
Spreadability test 
The spreadability of the formulated niosomal gels was measured by 
spreading 0.5 g of gel on a circle of 2 cm diameter pre-marked on a 
glass plate and then a second glass plate was employed [26]. A 5 g 
weight was permitted to rest on the upper glass plate for 5 min [27]. 
The diameter of the circle after spreading of the gels was determined. 
In vitro permeation through cellulose membrane 
Half g of each formulation containing 10 mg of HQ was transferred to 
a dissolution cell to which a cellulose membrane of the molecular 
weight cut off 10,000 was attached to one side and the other side of 
the tube was attached to the stem of the dissolution apparatus and 
immersed in a beaker of the dissolution apparatus containing 100 ml 
of PBS (pH 7.4). The temperature of the medium was maintained at 
37±0.5 °C. At specified time intervals for 24 h, 4 ml samples were 
withdrawn, and the drug was determined spectrophotometrically at 
λmax
Accelerated stability testing  
295 nm. Each sample withdrawn was replaced by an equal 
volume of PBS (pH 7.4). 
The stability of HQ from niosomal gel formulations was studied 
using accelerated stability testing for 2 mo at 4 °C, 25 °C, and 37 °C. 
The entrapment efficiency was measured after 7, 14, 21, 30, 45 and 
60 d. Also; the expiry date t90
Clinical evaluation of HQ niosomal gel formulation 
 was estimated [28].  
Study design 
This study is a randomized prospective comparative controlled trial. 
It was carried out on Sixty Egyptian female patients with different 
clinical varieties of melasma. The patients were diagnosed clinically 
on the basis of the typical appearance of skin lesions and confirmed 
by Dermoscopic examination. The patients were selected from the 
Outpatient Clinic of Dermatology and Venereology Department, 
Tanta University Hospitals and the patients were identified by coded 
numbers to maintain privacy. The study was carried out after 
approval of the Medical Ethics Committee number 68 and written 
informed consent from patients. Patients were being randomized 
into two groups:  
The group I 
Thirty patients with melasma were treated topically with niosomal 
gel of HQ 2% (span80: cholesterol: tween40) in 2% carbopol, which 
prepared in the laboratory of pharmaceutics and industrial 
pharmacy department, Faculty of Pharmacy (Girls branch)-Al-Azhar 
University. The gel was applied to the melasma lesions of the face 
once daily at night until a clinical cure or maximum of three months.  
The group II 
Thirty patients with melasma were treated with commercial topical 
HQ 2% cream (Clearique 2%) ®-
Inclusion criteria 
Delta Pharma Company-Cairo-Egypt 
to the melasma lesions of the face once daily at night for the same 
duration as the other group of patients. 
Newly diagnosed cases, patients who didn’t receive treatment for 
melasma in the previous 6 w before starting the pharmacotherapy 
were eligible for this study. Patients who agreed to join the study 
and signed a written consent and continued till the end of the follow-
up period were enrolled in the research. 
Exclusion criteria 
Pregnancy, miscarriage or nursing women, the use of hormonal 
therapy or contraceptive pills in the last 12 mo before the study and 
melasma patients who have systemic or other dermatological 
diseases were omitted from the research. Special emphasis on 
patients’ occupations and exclusion of those with inevitable sun 
exposure and patients who did not complete the treatment or the 
follow-up. 
Methods 
All the studied patients were subjected to a standard protocol 
which consists of 
Complete history taking for detailed clinical history; including the 
duration of the disease, evolution, precipitating or aggravating 
factors, any associated illness and previous treatment. General 
examinations to exclude patients with systemic diseases associated 
with hyperpigmentation as thyroid disease, Cushing’s disease, 
adrenogenital syndrome, liver diseases, renal diseases and 
hypermelanosis of drug origin. Dermatological examination was 
done to exclude patients with skin diseases other than melasma and 
to evaluate the melasma lesions clinically. 
Determination of modified melasma area and severity index (MASI) 
for clinical assessment of the patients’ condition before and after 
therapy was scored as follows:  
Modified MASI score = 0.3 A (F) D (F)+0.3 A (lm) D (lm)+0.3 A 
(rm) D (rm)+0.1 A(c) D(c) [29, 30] 
(A) area of involvement and (D) darkness, with the (F) forehead, left 
malar region (lm), right malar region (rm), and chin (c), corresponding 
to 30%, 30%, 30% and 10% of the total face, respectively. The area of 
involvement in each of these 4 regions was given a numeric value of 0 
to 6 (0 = no involvement; 1 =<10%; 2 = 10%-29%; 3 = 30%-49%; 4 = 
50%-69%; 5 = 70%-89% and 6 = 90%-100%). 
Darkness was rated on a scale from 0 to 4 (0 = absent; 1 = slight; 2 = 
mild; 3 =marked and 4 = maximum). It was calculated by multiplying 
the value of the area of involvement by the severity rating for 
darkness, for each of the 4 facial regions. The range of the total score 
was from 0 to 24 [29]. 
Digital photography registration 
Baseline photographs (frontal, right and left views) were taken for 
the face of every patient to document the pretreatment skin lesion 
and at the end of therapy and during follow up period to evaluate 
the clinical efficacy and safety of the treatment. 
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The Fitzpatrick skin type is a commonly utilized framework to 
define a person’s skin type in terms of reaction to ultraviolet 
radiation (UVR) exposure. 
The current Fitzpatrick skin type classification indicates six different 
skin types, skin color, and reaction to sun exposure which varies 
from very fair (skin type I) to very dark (skin type VI) dependent on 
whether the patient burns at the first average sun exposure or tans 
at the first average sun exposure. The two primary variables that 
impact skin type are genetic factors and response to sun exposure 
and tanning habits. The Fitzpatrick scale is a numerical classification 
outline for determining the skin color based on a questionnaire 
related to an individual’s genetic structure, reaction to sun exposure, 
and tanning habits [31]. The response to each question is measured 
on a scale of zero to four. The response for all the questions is added 
to get the ultimate score corresponding to the Fitzpatrick skin type. 
Skin type score was given a number from 0 to>30 as follows (0 to 7: 
type I, 8-16: type II, 17-25: type III, 25-30: type IV and over 30 skin 
type V-VI [32]. 
Follow-up 
After the end of the therapy, the patients were evaluated clinically 
every month for a period of 3 mo to detect any recurrence or 
complications. 
Assessment of clinical response to the pharmacotherapy  
Physician’s opinion: Clinical evaluations were done before starting 
the therapy and every two weeks during the treatment by three 
dermatologists. 
Patient’s opinion and questionnaire: The patients were asked to 
give an accurate value for the percentage of improvement. They 
were asked to rate on a scale of 1-5 (l=no response; 2=fair 
improvement; 3=good improvement; 4=very good improvement; 
5=excellent improvement). 
Digital image analysis of standard colored photographs was 
used to determine the percentage of improvement of the melasma 
lesions. 
Assessment of the clinical efficacy was categorized as modified 
MASI score 
No response: no changes in modified MASI score at the end of the 
therapy. Fair response: less than 25% fall in modified MASI score. 
Moderate response: 25 to 50% fall in modified MASI score. Very 
good response: 50 to 75% fall in modified MASI score. Excellent 
response: more than 75% fall in the modified MASI score. 
Safety assessment 
It was conducted for all patients at each visit, every two weeks, after 
enrollment in the study. All clinical medical events, whether 
observed by the investigator or reported by the patient and whether 
or not thought to be drug-related, were considered adverse events. 
Follow up assessment period 
The patients were followed up and evaluated clinically and by 
colored photographs monthly after the end of the therapy for 3 mo 
to determine the degree of improvement or recurrence of the 
melasma lesions. 
RESULTS AND DISCUSSION 
Observation of niosomes under a light microscope 
Photomicrographs (fig. 1) using a light microscope showed that 




Fig. 1: Photomicrographs taken with a light microscope of the prepared niosomal formulations 
 
Entrapment efficiency  
The obtained values showed that HQ has been successfully 
incorporated into the niosomes core (fig. 2). It was obvious that 
Tween 40 and Tween 60 containing formulae had higher 
encapsulation efficiency (98.59 and 96.9%, respectively) compared 




Fig. 2: Entrapment efficiency of HQ niosomes 
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Transmission electron microscope (TEM) microphotographs 
It gives a sub-nanometer resolution of the observed formulation. 
Niosomal vesicles appeared as spherical and unilamellar vesicles. 
The vesicles appear distinct and not aggregated or coalesced. The 
formulated niosomal vesicles were found to be spherical in shape, 
ranging from 10.4 nm to 32.2 nm in size (table 3), (fig. 3, 4). 
Zeta potential measurement 
The values of zeta potential for F2 and F3 are illustrated (table 3), which 
was found −27 mV and-21.9 mV for F2 and F3, respectively. This means 
the physical stability of the prepared noisome. The effect of HLB values 
of surfactants on zeta potential could be explained in terms of surface 
energy, which tends to increase with an increase in HLB values towards 
the hydrophobicity. The increase in surface energy of the vesicles leads 
to increase in the values of zeta potential towards negative. As the zeta 
potential increases, the charged particles repel one another, and this 
stabilizes the system against aggregation. Systems of the zeta potential 
value of±30 mv or higher are considered to be stable [20]. 
Release of HQ from niosomes 
In vitro release of HQ from niosomes 
The HQ loaded niosomes slowed down the release of HQ compared 
with the free drug solution, which released nearly (96.8±2.6) of the 
drug within 8 h, so there is an efficacy of the niosomal formulations 
in prolonging the release rate of the drug. From the release data of 
HQ from niosomes, it can be noticed that the release occurred in two 
distinct phases, an initial burst release, which lasted from 2-4 h, 
followed by a sustained but reduced release, which was maintained 
for at least 24 h. This biphasic release pattern may be due to the size 
heterogenicity of the vesicles [33] (fig. 5). 
 
 
Fig. 3 TEM of F2 
 
 
Fig. 4: TEM of F3 
 
 
Fig. 5: In vitro release study of the prepared formulations 
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Color, homogeneity and texture 
All niosomal gel formulations were milky white colour. Revealed 
physical characters of niosomal gel formulations. F2a2, F3a2 and F2b3 
were with the very good homogenous appearance and with the best 
smooth texture. F2a1, F2b2, F3a1 and F3b2 were with good 
homogenous appearance but with much-liquefied texture (could not 
adhere quickly on patient skin). F2a3, F2b4, F3a3, F3b4, F3b3 and 
F3b2 were with little homogenous appearance and with hard texture. 
pH values 
The pH values of all the prepared formulations ranged from 
5.69±0.09 to 6.92±0.06, which probably would not produce skin 
irritation. 
Spreadability 
Spreadability of the topically applied formulation is an important 
property considering patient compliance. Formulations with higher 
spreadability values allow ease of application and thereby increased 
surface area available for drug permeation [34]. F2a2, F2b3 and 
F3a2 had a diameter between 4 and 4.3, which indicates good 
spreadability. F2a1, F2b2, F3a1, F3b2 and F3b3 had a diameter 
between 4.4 and 4.7 cm. F2a3, F2b4, F3a3 and F3b4 had a diameter 
between 3 and 3.3 cm. These results agreed with (Yogeshwar and 
Vandana, 2010) [35] who mentioned that good spreadability is 
above 3.5 cm  
In vitro permeation studies through cellulose membrane 
Effect of concentration of Carbopol 934 as a gelling agent on the 
permeation of HQ from niosomal gels: The effect of Carbopol 934 
concentration on the permeation of HQ from the formulated niosomal 
gels across a cellulose membrane was studied for the selection of a 
suitable concentration of Carbopol 934 required for producing gel with 
suitable consistency for topical application  (fig. 6) shows the permeation 
of HQ from niosomal gel F2 and F3 prepared with different Carbopol 934 
concentrations (1%, 2% and 3% w/w). The results indicate that the 
permeated amount of HQ decreased with an increasing concentration of 
Carbopol 934 from 1% to 3%. This decrease of the permeated amount 
may be related to the higher resistance to drug diffusion by agreement 
with that previously mentioned by (El-Megrab et al., 2006), [34]. They 
stated that gel having a compact and close structure may have a slower 
release rate than one of lower consistency. It was observed that the 
formulations prepared with 2% w/w Carbopol 934 produced gel with a 
consistency suitable for topical application, so it was chosen to prepare 
all the gel formulations in this study. The same occurred in a case of CMC 
Na as shown in (fig. 7), which shows the permeation of HQ from 
niosomal gel F2 and F3 prepared with different CMC Na concentrations 








Fig. 7: the permeation of HQ from niosomal gel F2 and F3 prepared with different CMC Na concentrations (2%, 3% and 4% w/w) 
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Accelerated stability studies of niosomal gel formulations of HQ 
The Accelerated stability studies of niosomal gel formulations of HQ 
were done at 4 °C, 25 °C and 37 °C and the formulations were ranked 
according to t90 
Melasma is procured and symmetrical hyper melanosis, ordinarily 
spread broadly on the malar eminence and cheek, and less regularly 
on the forehead and upper lip. Melasma usually appears in female 
patients in their 30s or 40s after pregnancy or contraceptive pills 
utilization, recommending that the triggering of melasma is 
hormonally related [36]. Melasma can be especially distressing to 
the patients and has appeared to affect a patient’s quality of life. 
Since of its dermal component and liability to relapse, it is often 
challenging to be treated. The treatment of melasma is usually 
unacceptable due to the great recurrence of lesions and the absence 
of a definitive brightening alternative [37]. In this study, we tried to 
solve these problems by preparing HQ in niosomal gel formulations.  
values as shown in (table 4) 
Before starting the pharmacotherapy, there were non-significant 
differences in preliminary data between the studied two groups 
regarding the age, sex, duration of melasma, Fitzpartic skin type, 
precipitating factors, dermoscopic type and pattern of melasma, and 
modified MASI score. 
 
Table 4: Rank order of HQ niosomal gel formulations according to t90 
Formulations 
values 
t90 Rank order (days) at 20 °C 
F2a2 97.64371 1 
F2b3 65.4377 2 
F3a2 54.36394 3 
 
Table 5: Preliminary data of the patients 
 Group I No=30 Group II No=30 T/X P-value 2 
Age (year) Range  20–60  22–58  0.028 0.867  
Mean  38.37±12.25  37.87±10.65  
Sex (%) Male  33.3 26.7 0.317 0.573 
Female  66.7 73.3 
Duration (%) <1 y  13.3 13.3 0.087 0.957 
1-5 y  60.0 56.7 
>5 y  26.7 30.0 
Fitzpartic (%) III  40.0 36.7 0.071 0.791 
IV  60.0 63.3 
Precipitating factors (%) Sun exposure 56.7 46.7 2.401 0.662 
Pregnancy 0.0 6.7 
Hormonal medication 13.3 16.7 
Positive F H 13.3 13.3 
Cosmetics use 16.7 16.7 
Type (%) 
 
Epidermal 30.0  26.7 0.087 0.957 
Mixed 56.7 60.0 
Dermal 13.3 13.3 
Pattern of melasma (%) Centrofacial 60.0  66.7 0.287 0.592 
Malar 40.0 33.3 
Modified MASI Range  0.8–18.7  0.9–18.3  P: 0.889 
Mean   8.41±5.82 8.63±6.09 
GroupI: applied niosomal gel, GroupII: applied Clearique® 2% delta pharma, Positive F H: positive family history, MASI: melasma area and severity 
index, age and modified MASI are presented as mean±SD, * P<0.05: statistically significant difference 
 
There was a significant difference in clinical response, complications 
of the therapy, duration till improvement, recurrence of melasma 
and modified MASI score between the two groups after the end of 
the therapy. 
  
Table 6: Clinical response to the therapy, side effects, duration till improvement, and recurrence of melasma in the studied groups 
 Group I No=30 Group II No=30 T/X P-value 2 
Clinical response (%)  No  0.0 30.0 13.672 0.008* 
Fair  6.7 13.3 
Moderate 6.7 0.0 
Very good 56.7 40.0 
Excellent 30.0 16.7 
Duration till improvement (W)  Range 3–28 5-30 28.103 0.001** 
Mean  9.88±7.57 19.75±6.83 
Modified MASI 
 
Range 0.3–3.8  0.4–18.3  P: 0.011* 
Mean  1.09±0.84 3.36±4.63 
Complications (%)  No 90.0 0.0 50.178 0.001** 
Burning sensation 0.0  20.0 
Erythema 3.3 30.0 
Dryness and scaling 6.7 23.3 
Pruritus 0.0 26.7 
Recurrence of melasma No 80.2 53.3 4.800 0.028* 
Yes 20.0 46.7 
GroupI: applied niosomal gel, GroupII: applied Clearique® 2% delta pharma, MASI: melasma area and severity index, duration till improvement and 
modified MASI are presented as mean±SD, * P<0.05: statistically significant difference, ** P<0.001: a highly statistically significant difference. 
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In the current study, assessment of the clinical response of the therapy 
was done by physicians’ opinions, patients and digital photographs every 
4 w and modified MASI score at base and at the end of the therapy. 
In this research, excellent results occurred in 23.3% of the patients, 
very good in 48.8%, good in 3.3%, fair results in 10% and no 
response in15% of the patients. Excellent and very good responses 
were occurred predominantly in group I. The best response to the 
therapy was in epidermal type than in mixed and dermal types in 
groups I and II. This may be explained by the presence of melanin in 
epidermal melasma in superficial epidermal cells, which is easily 
penetrated by the topical therapy and replaced more often, but in 
dermal melasma, melanin is engulfed by melanophages deep in the 
dermis and require a high penetration influence of the topical 
therapy. As well as the best response was in patients with melasma 
duration<5 y than those with melasma duration>5 y in groups I and 
II. This may be explained by the transformation of epidermal 
melasma to mixed or dermal type on long duration of the disease 
and may be due to the cumulative effect of sun exposure. 
Our results are in accordance with a comparative study of HQ and 
kojic acid in the treatment of Melasma by (Gajjala et al., 2016) [38]. 
This study clearly demonstrated a positive effect of kojic acid cream 
2% on melasma lesions, with improvements of 10%, 22% and 32%, 
seen at the end of the first, second and third month, respectively. In 
contrast, the positive response to treatment with HQ cream 2% at 
the end of the first, second and the third month were 7%, 24% and 
53%, respectively. 
Regarding to the duration of therapy till achievement of the clinical 
improvement, in the niosomal gel group it ranged from 3-28 w with 
a mean 9.88±7.57and 5-30 w with a mean 19.75±6.83 in the 
commercial product group that revealed a highly significant 
decrease in the period needed to attain clinical efficacy in the group 
used niosomal gel (** p<0.001). These results are consistent with 
those of (Hadded et al., 2003) [39] whose patients improved after 12 
w of treatment with HQ alone. 
Modified MASI score improved significantly in both groups after the 
therapy compared to before the therapy as well as there was a 
significant decrease in modified MASI score in the niosomal group 
after treatment in comparison to the commercial group *P<0.05. In a 
recent study by (Samreen Rafi et al., 2017) [40] who compared the 
efficacy of topical HQ 2% and oral tranexamic acid 500 mg daily in 
patients of melasma. Their results showed that in HQ group, the 
mean MASI at baseline was 40.42±4.74 and at the end of 8-week 
therapy, it reduced to 13.33±3.29; there was 67.02±9.51% reduction 
in the mean MASI score (*p<0.05) that in agreement with our 
results.  
Safety assessment: In group I, 90% of the patients experienced no 
complication and one patient that represents 3.3% experienced mild 
erythema (duration of erythema ranged between 7 to 14 d). This 
was resolved by application of a cold compress and a bland 
emollient and 6.7% experienced dryness and scaliness at the site of 
application after 4 w of starting the therapy which resolved by a 
bland emollient. In group II, 30% experienced erythema, 23.3% 
experienced dryness and scaliness and 26.7% experienced pruritus 
at the site of application, which resolved gradually in 7 d. 20% of the 
patients experienced a severe burning sensation, which resolved 
spontaneously. These results showed a high significant reduction in 
side effects in the niosomal group (**p<0.001). In the previous study 
by (Gajjala et al., 2016) [38], 53% of patients who had melasma 
lesions on the left side treated by HQ cream 2% complained about 
erythema and burning sensation side effects. On the other hand, only 
26% of those treated by kojic acid (on the right side of the face) 
cream did so. The lower side effects in the current study in patients 
treated with niosomal gel may be due to the prevention of direct 
contact of skin with HQ as it was encapsulated in niosomes. Also the 
presence of surfactant, co-surfactant and carbopol in our formulae 
caused the demulcent and cold sensation at the site of application. 
In this study, the patients were evaluated monthly for 3 mo after the 
end of depigmentation therapy. The recurrence of melasma had 
occurred in 6 patients (20%) in the niosomal gel group and 14 
patients (46.7%) in the commercial product group that revealed a 
statistically significant decline in the reappearance of melasma in 
niosomal gel group (*p<0.05). Sun exposure was the most important 
precipitating factor related to recurrence, which suggests the major 
role of ultra-violet rays in the etiology of melasma lesions. 
 
 
Fig. 8:  Patients before and after treatment 
 
CONCLUSION 
The current work succeeded in proving that incorporating HQ in 
niosomal gel improves its therapeutic effect regarding clinical 
efficacy, shorter duration of treatment, nearly absence of side effects 
and lesser recurrence. Niosomal gel of HQ also demonstrated that it 
has better patient compliance than Clearique 2%® delta pharma 
since the second one causes erythema, pruritus and burning 
sensation at the site of application.  
Salem et al. 
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